From Steritas LLC Nov 25 2024 Steritas LLC., a company dedicated to enhancing care for steroid-treated patients, today announced a licensing agreement with argenx, a global immunology company, for use of its STOX ® Suite of steroid-toxicity clinical outcome assessments (COAs) across argenx's development programs for differentiated immunology therapeutics. The STOX Suite comprises first-in-class digital instruments that provide a standardized and validated measure of the full scope of steroid-